Rauschert, C., Möckl, J., Seitz, N.-N., Wilms, N., Olderbak, S., Kraus, L.
The use of psychoactive substances in Germany—findings from the Epidemiological Survey of Substance Abuse 20212022
Deutsches Ärzteblatt International, 119(527–34). doi: 10.3238/arztebl.m2022.0244
The fulltext (open access) can be found on the Journal´s website
https://www.aerzteblatt.de/int/archive/article/226333
Background: Monitoring the use of psychoactive substances and substance-related problems in the population allows for the assessment of prevalence and associated health and social consequences.
Methods: The data are derived from the Epidemiological Survey of Substance Abuse (ESA) 2021 (n = 9046, 18–64 years). We estimated prevalence rates of the use of tobacco, alcohol, illegal drugs, and psychoactive medications, as well as the prevalence rates of their problematic use (indicating dependence) using screening instruments, and extrapolated the results to the resident population (N = 51 139 451).
Results: Alcohol was the most frequently used substance, with a 30-day prevalence of 70.5% (36.1 million people), followed by non-opioid analgesic drugs (47.4%; 24.2 million) and conventional tobacco products (22.7%; 11.6 million). E-cigarettes were used by 4.3% (2.2 million) and heat-not-burn products by 1.3% (665 000). Among illegal drugs (12-month prevalence), cannabis was the most frequently used (8.8%; 4.5 million), followed by cocaine/crack (1.6%; 818 000) and amphetamine (1.4%; 716 000). Rates of problematic use among the study participants were 17.6% for alcohol (9.0 million), 7.8% for tobacco (4.0 million), 5.7% for psychoactive medications (2.9 million), and 2.5% for cannabis (1.3 million).
Conclusion: The consumption of psychoactive substances continues to be widespread in Germany. In view of the imminent legal changes, the high prevalence of cannabis use and its problematic use need to be taken into consideration.
IFT Institut für Therapieforschung
Leopoldstraße 175
80804 München
Tel. +49 89 360804-0
Fax +49 89 360804-19
Email: ift@ift.de